Clinical Trial Update: Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of a MUC1-targeted immunotherapy for unresectable stage III non-small cell lung cancer has been withdrawn, with Merck KGaA as sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MUC1-specific immunotherapy

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Non-small Cell Lung Cancer (NSCLC) Stage III | Phase 1 | Status: WITHDRAWN